Response to the editor by F. Di Berardino et al.
CHEST / 138 / 3 / SEPTEMBER, 2010  759www.chestpubs.org
alternative spacer, appropriate in vitro or in vitro and clinical data 
must be presented.  3  
 The proposed “amount of drug within the respirable range” is 
not enough to ensure equivalence from an in vitro point of view 
since the whole aerodynamic particle size distribution has to be 
compared.  3  If comparative in vitro determination using a vali-
dated method does not show equivalence, a clinical comparison 
is required. This clinical comparison must include an assessment 
of systemic safety through investigation of equivalence based on 
pharmacokinetic data or pharmacodynamic data.  3  
 From an effi cacy viewpoint the study must be sensitive enough 
to discriminate between spacers. For a study to have assay sensi-
tivity at least two non-zero levels need to be studied and one dose 
level needs to be shown to be superior to the other. Consequently, 
the proposed study design to assess “improvement of spirometric 
parameters” does not comply with the regulatory requirements  3 - 5  
and the state of the art,  2  consisting of the estimation of the relative 
potency. Furthermore, the authors have neither compared the 
results statistically nor predefi ned the acceptance range to con-
clude that both VHCs are equivalent. Therefore, it is not possible 
to conclude that “both of the VHCs tested were suitable for use in 
the delivery of salbutamol.”  1  The new VHC should be compared 
properly to be used and it should be used only with those pMDIs 
investigated. 
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 Response 
 To the Editor: 
 In reply to the response by García-Arietato regarding our pre-
vious correspondence,  1  we are pleased to see that we have attained 
our initial objective of drawing attention to and provoking dis-
cussion on the unacceptable situation concerning drug delivery 
through pressurized metered-dose inhalers (pMDI) and spacers. 
The main problem is that summaries of product characteristics of 
drugs in pMDIs currently available on the market often do not 
contemplate the use of valved holding chambers (VHCs), even 
if evidence suggests that they should not be used without them 
in order to avoid oropharyngeal deposition, and do not report 
instructions for use or therapeutic dose when administered with 
specifi c VHCs. Moreover, it has even been suggested that plastic 
or glass bottles can be used instead of VHCs. On the basis of 
this evidence, many patients probably do not use drugs properly 
delivered by pMDIs and do not receive the optimal therapeutic 
dose. 
 We agree that if a pMDI has been designed for use with a 
specifi c spacer it should always be used with this named spacing 
device.  2  In this case, however, both should be present in the same 
package to avoid misuse and must be reported in the product 
warnings, for example, “These instructions are not necessarily 
valid when this pMDI is used with other spacers.” 
 Aerosol therapy is a complex process that depends on nebu-
lizer performance and patient features. In order to avoid errors, 
these variables should be studied separately. The amount of drug 
within the respirable range is an objective parameter to quantify 
the amount of drug available at the end of the spacer system and 
poten tially capable of reaching the lower airways. This simple 
method has been suggested to standardize fi rst-step aerosol 
therapy delivery  3  and is currently the only way of assessing the 
effective amount of drug administered. Moreover, if comparative 
in vitro determination does not show equivalence, it is highly 
likely that either will clinical comparison. If pMDI drugs are to be 
used with different spacers, instructions must be given about how 
to make the same effective amount of drug to be administered 
available at the end of each spacer. Our results were supported by 
statistical analysis, particularly a general linear model for repeated 
measures using type of treatment and sex as factors and age as 
covariate. FEV 1 ( F  5 28.733;  P  , .001) and peak expiratory fl ow 
( F  5 25.879;  P  , .001) were shown to increase signifi cantly after 
both treatments. 
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 Occlusion and Malposition of 
Small-Bore Chest Tubes for 
Pleural Infection 
 To the Editor: 
 We read with great interest the recent study by Rahman et al 
(March 2010),  1  which suggests that smaller tubes are as effective for 
the treatment of pleural infection as larger-bore tubes, while causing 
less pain. However, no mention was made of two complications that 
smaller tubes may be more prone to: malposition and occlusion. 
 Although we are not aware of published data, common sense sug-
gests that occlusion of chest tubes used to drain thick fl uid, such as 
pus, may occur more readily with small-bore tubes. Remérand et al  2  
showed that chest tube malposition is fairly common (30% in their 
series), and that avoiding the use of a trocar reduces the risk of mal-
position. There are, however, no data regarding guidewire insertion. 
 Despite the fact that tube size was not randomly assigned, we 
would be very interested to know what the incidence of these com-
plications was in the authors’ series. If they were more frequent 
with small-bore tubes, that would be an argument against the use 
of these tubes. Obviously, both this hypothesis and the authors’ 
conclusion that small-bore tubes yield similar clinical outcomes to 
large-bore tubes will have to be tested in randomized studies. 
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 Response 
 To the Editor: 
 We share the interest and concern of Drs Atchabahian, Laplace, 
and Tazarourte in the quality of care patients receive with chest 
tube drainage. We agree that there is a compelling need for ran-
domized trials to accurately defi ne effi cacy and safety of different 
tube sizes and insertion techniques. Until such trials are com-
pleted, it is not possible to know with certainty which tube types 
are in the best interests of patients, and we must rely on nonran-
domized data sets. Against this background, our cohort represents 
the largest comparative study to date and so helps to inform the 
debate about this important treatment. 
 Although it seems intuitive that smaller tubes become blocked 
during the drainage of infected purulent fl uid, there is extensive 
observational (nonrandomized) literature suggesting that this is 
not the case in practice, particularly with regular fl ushing.  1 , 2  The 
lack of therapeutic advantage in our large series  3  supports the 
conclusion that there is no clear disadvantage to smaller bore 
tubes. Within our study, the rate of malposition or occlusion 
requiring reinsertion of a second tube is captured within the 
results and discussed in the article. We continue to believe that 
our data provide preliminary encouraging evidence that smaller 
bore tubes may achieve as good a clinical outcome with less 
pain for patients, and we eagerly anticipate the results of well-
designed randomized trials to defi nitively assess whether this 
is true. 
 Najib M.  Rahman ,  BMBCh 
 Robert J. O.  Davies ,  DM 
 Oxford, England 
 Affi liations:  From the Oxford Centre for Respiratory Medicine 
and Oxford Respiratory Trials Unit, University of Oxford. 
 Financial/nonfi nancial disclosures: The authors have reported 
to  CHEST that no potential confl icts of interest exist with any 
companiesorganizations whose products or services may be dis-
cussed in this article. 
 Correspondence to: Najib M. Rahman, BMBCh, Oxford Respi-
ratory Trials Unit, Oxford Centre for Respiratory Medicine, 
Churchill Hospital Site, Oxford Radcliffe Hospital, Old Road, 
Anesthesiology (Dr Laplace), Hôpital Bicêtre; and the Hôpital 
Marc Jacquet (Dr Tazarourte). 
 Financial/nonfi nancial disclosures: The authors have reported 
to  CHEST that no potential confl icts of interest exist with any 
companiesorganizations whose products or services may be dis-
cussed in this article. 
 Correspondence to: Arthur Atchabahian, MD, Department of 
Anesthesiology, New York University/Hospital for Joint Diseases 
Medical Center, 301 E 17th St, New York, NY 10003; e-mail: 
 arthur.atchabahian@gmail.com 
 © 2010 American College of Chest Physicians.  Reproduction 
of this article is prohibited without written permission from the 
American College of Chest Physicians ( http :// www . chestpubs . org /
 site / misc / reprints . xhtml ). 
 DOI: 10.1378/chest.10-0811 
 References 
  1 .  Rahman  NM ,  Maskell  NA ,  Davies  CWH ,  et al .  The relation-
ship between chest tube size and clinical outcome in pleural 
infection .  Chest .  2010 ; 137 ( 3 ): 536 - 543 . 
  2 .  Remérand  F ,  Luce  V ,  Badachi  Y ,  Lu  Q ,  Bouhemad  B ,  Rouby 
 JJ .  Incidence of chest tube malposition in the critically ill: 
a prospective computed tomography study .  Anesthesiology . 
 2007 ; 106 ( 6 ): 1112 - 1119 . 
